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Background: Cytomegalovirus (CMV) is associated with morbidity and mortality in HIV-
exposed infants. We assessed the effect and relative contribution of breastfeeding on infant CMV 
acquisition in the setting of maternal HIV infection.  
Methods: Between 1993-1998 pregnant, HIV-infected women in Nairobi, Kenya were 
randomized to breastfeeding or formula feeding in an HIV transmission study. Women were 
allocated equally between treatment arms, and the study was not blinded. The primary endpoint 
of this nested study was time to infant CMV infection.  
Results: CMV infection was assessed in 138 breastfed and 134 formula-fed infants. Baseline 
characteristics were similar between arms. Breastfed infants acquired CMV earlier than formula-
fed infants (median 4.26 vs. 9.87 months, p<0.001), and had a higher 1-year probability of CMV 
infection (0.89 vs. 0.69, p<0.001). Breastfeeding was associated with a 1.6-fold increased risk of 
infant CMV independent of infant HIV status (multivariable HR=1.61, 95%CI=1.20-2.16, 
p=0.002). Approximately one third of CMV infections occurred peripartum, 40% through 
breastfeeding, and the remainder through non-breast milk modes.  
Conclusion: Preventing CMV acquisition may be a priority for HIV-exposed infants, but there is 
a narrow window of opportunity for intervention. Approaches that reduce maternal cervical and 
breast milk CMV reactivation may help delay infant infection. 
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Introduction 1 
Cytomegalovirus (CMV) infects a large proportion of HIV infected adults and children, and 2 
plays a role in HIV pathogenesis that is not well understood. In addition to being an important 3 
opportunistic pathogen in severely immunosuppressed individuals, CMV infection is associated 4 
with a number of adverse outcomes in HIV-infected individuals. CMV viremia is independently 5 
associated with increased HIV disease progression and mortality [1-3]. In HIV-infected and 6 
exposed uninfected infants, CMV infection has been associated with mortality, developmental 7 
delays, neurologic sequelae, and elevated immune activation [2-8].  8 
Transmission rates are high between HIV-infected mothers and their children; in Kenya >80% of 9 
HIV-exposed infants acquire CMV before three months of age [9]. A recent report from the 10 
Breastfeeding, Antiretrovirals and Nutrition (BAN) Study reported a CMV prevalence of 70% at 11 
6 months of age in HIV-exposed infants from Malawi [10]. Infant CMV acquisition can occur in 12 
utero, intrapartum, or via contact with infected breast milk, saliva, or urine [11-14]. 13 
Approximately a third of healthy pregnant women experience CMV reactivation in the cervix 14 
during the third trimester [15-17], and nearly all women have CMV DNA detectable in breast 15 
milk [18, 19]; virus replication in these compartments are associated with infant infection. The 16 
kinetics of breast milk CMV reactivation appear to differ according to HIV status. In HIV-17 
uninfected women, Yasuda and colleagues reported that by 2 weeks postpartum most breast milk 18 
specimens had detectable CMV DNA with copy number peaking at 4-6 weeks postpartum in the 19 
range of 104-106 copies/ml, declining rapidly in the following 2-4 weeks [20]. In Kenyan HIV-20 
infected women, CMV loads peaked at 5.5 log10 copies/ml at 2 weeks postpartum but remained 21 
very high for 6 months [21]. Although each of these routes of transmission are understood to be 22 
important, their relative contribution to CMV infection in HIV-exposed children is unknown. A 23 
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better understanding of the timing and routes of CMV transmission from HIV-infected women to 24 
their infants is important in designing interventions to prevent or delay CMV transmission, and 25 
in the strategic deployment of a CMV vaccine for this population.  26 
We utilized specimens and data from an historic randomized trial of mother-to-child HIV 27 
transmission, in which Kenyan HIV-infected women were randomized to breastfeed or formula 28 
feed their infants [22]. In this study, we compared rates of CMV infection in HIV-exposed 29 
infants randomized to breastfeeding versus formula feeding, and estimated the relative 30 
contribution of peripartum, breast milk, and other non-breast milk postnatal transmission. 31 
Materials and Methods 32 
Study Design The study was approved by the Institutional Review Board of the University of 33 
Washington and the Ethics and Research Committee of Kenyatta National Hospital; all 34 
participants provided written informed consent for participation and human experimentation 35 
guidelines of the University of Washington were followed. This is a retrospective analysis of 36 
specimens collected during a randomized controlled trial (RCT) of breastfeeding versus formula 37 
feeding and HIV-1 transmission, conducted in Nairobi, Kenya between 1993 and 1998 [23]. We 38 
assumed the rate of CMV acquisition in the breastfeeding arm would be similar to our previous 39 
observational study in Kenya, which was 90% by six months of age [9]. With equal allocation to 40 
study arms, and estimating that 300 infants would meet eligibility criteria, the study was powered 41 
to detect a 30% difference in transmission between arms, us eta=0.80 42 
lpha=0.05, assuming a two-sided test. Eligibility criteria for the RCT included pregnancy 43 
of <32 weeks gestation, willingness to have feeding modality randomized, access to clean 44 
municipal water, and intent to reside in Nairobi for >2 years. For the purpose of this sub-study, 45 
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we included all infants who had had dried blood spot (DBS) specimens collected before 14 46 
weeks of age. 47 
Cohort and randomization. This trial was conducted before antiretroviral therapy (ART) for 48 
prevention of mother-to-child HIV transmission became available in Kenya; all women and 49 
infants were ART naïve. At enrollment, caregivers provided sociodemographic and medical 50 
histories and underwent a clinical examination. At approximately 32 weeks gestation, women 51 
were randomized to breastfeed or formula feed at a 1:1 ratio, using computer-generated block 52 
randomization. Treatment allocation was not blinded to study staff; assignment to study arm was 53 
revealed to women and clinicians via pre-sealed envelopes. In the formula group, safe formula 54 
preparation was demonstrated during home visits, and women were provided with free dried 55 
milk formula throughout the study. Women and infants were assessed in clinic monthly in the 56 
first year and quarterly during the second year of an infant’s life and as needed for illness. 57 
Postnatal visits included assessment of both mother’s and baby’s clinical status, as well as infant 58 
growth and feeding. Infant blood was collected at birth, six weeks, 14 weeks, and every three 59 
months until 24 months of age for HIV testing [23]. Women delivering at home or another 60 
facility were asked to bring their newborns to the study clinic for clinical examination and HIV 61 
testing as soon as possible following delivery. Infant HIV diagnosis was conducted in this study 62 
using PCR for HIV gag DNA detection in peripheral blood mononuclear cells or dried blood 63 
spots (DBS) as previously described [22, 24]. Due to the high incidence of infant HIV infection 64 
in the breastfed arm, in April 1998 the DSMB closed the study early, and recommended that 65 
breastfeeding women be advised to stop breastfeeding and be given formula [23]. 66 
CMV diagnostics. All CMV viral loads were measured from DBS as previously described [21]; 67 
plasma specimens from this study have been extensively used in vertical transmission studies 68 
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over the past decade, and were no longer were available for longitudinal CMV assessments. In 69 
our assay, when CMV loads are above 300 copies in plasma the two assays are comparable for 70 
CMV detection, although they return lower CMV viral load measurements (Atkinson, manuscript 71 
in preparation). CMV viral loads were measured in all specimens for each infant up to 12 72 
months of age. The lower limit of detection was 100 copies/ml.  73 
Infants with no detection of CMV DNA throughout follow-up received serologic testing of their 74 
last-collected plasma specimen closest to 12 months of age to determine final infection status; 75 
only plasma specimens collected beyond six months of age were included for serology to avoid 76 
confounding by maternal antibodies. ELISA was used to detect a panel of antibodies targeting 77 
CMV IgG (CMV ELISA II Test Kit Wampole Laboratories, Princeton, NJ). 78 
Statistical analysis. All analyses were intent-to-treat and were performed using IBM SPSS 79 
Statistics Version 20.0 (IBM Corporation). Baseline characteristics for infants included in the 80 
CMV analyses were compared between randomization arms using Mann Whitney U tests for 81 
continuous variables and Chi-square tests for categorical variables. HIV-exposed uninfected 82 
infants were defined as infants with their last CMV test at or after their last HIV negative test 83 
and who were never diagnosed with HIV infection. The proportion of infants infected with CMV 84 
at birth were compared between arms using Fisher’s Exact test; the proportion with CMV DNA 85 
detection and the proportion with CMV antibody detection were compared between arms using 86 
Pearson’s Chi-square tests. Time to CMV infection was compared between arms using Kaplan 87 
Meier Curves and the log-rank test. Z-tests were used to compare median time to CMV infection 88 
and the probability of CMV infection at one year. Cox proportional hazards models were used to 89 
assess the independent effects of time-varying HIV infection status and feeding modality as well 90 
as any potential effect modification of these two variables on CMV acquisition.  91 
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In addition to the intent-to-treat analyses described above, all analyses were performed 92 
categorizing infants as breastfed or formula-fed based on the mother’s self-reported feeding 93 
history. For these analyses, infants whose mothers ever reported breastfeeding were classified as 94 
breastfed and infants whose mothers never reported breastfeeding were classified as formula-fed. 95 
Estimates of the proportion of CMV infections attributable to different modes of transmission in 96 
the first year of life were obtained by comparing the proportions of infants with CMV DNA 97 
detection in the breastfed and formula fed infants at defined time-points. Because of interval 98 
sampling at delivery and six weeks of age, we were unable to discriminate in utero from 99 
intrapartum infections; we thus combined infections detected at or before 6 weeks of age as 100 
“peripartum” transmissions, which are presumed to primarily include in utero and intrapartum 101 
and potentially very early breast milk or saliva transmissions. Infections due to saliva and/or 102 
urine exposure were defined as those infections occurring at six weeks of age or later in the 103 
formula fed infants, and infections due to breast milk exposure were defined as the excess 104 
infections between the breastfed and formula fed infants at one year of age. Because 30% of the 105 
women randomized to formula elected to breastfeed [22], this analysis was conducted as-treated.  106 
Results  107 
Cohort characteristics The trial CONSORT diagram is provided in Figure 1. One hundred and 108 
thirty eight breastfed and 134 formula fed infants had CMV testing. Mothers in both arms were 109 
similar in terms of age, parity, and household size (Table 1). Median duration of breastfeeding 110 
was 14 months. At baseline, median prenatal CD4 count was similar between arms (p=0.2). 111 
Infants had a median of 11 (IQR: 6, 17) study visits in the breastfeeding arm and 13 (IQR: 8, 18) 112 
in the formula feeding arm (p=0.3) with a median of 4 (IQR: 3, 5) and 5 (IQR: 3, 5) of these 113 
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visits assessed for CMV DNA, respectively (p=0.2). As previously reported [22], breastfed 114 
infants were significantly more likely to acquire HIV than formula fed infants (34.06% versus 115 
14.93%, p<0.001) and mothers in the formula feeding arm were significantly more likely to cross 116 
over treatment arms (defined as ever breastfeeding) compared to those in the breastfeeding arm 117 
(defined as never breastfeeding) (26.12% versus 4.35%, p<0.001). 118 
Feeding allocation and CMV acquisition A total of 1103 infant samples were tested for CMV 119 
DNA; 547 (49.59%) in the 138 breastfed infants and 556 (50.41%) in the formula fed infants. 120 
Overall, 20.1% of these samples had detectable CMV DNA, with 23.95% positive in the 121 
breastfeeding arm and 16.37% positive in the formula feeding arm.  122 
The rate of CMV DNA detection at birth was 3.73% in the formula-fed infants and 3.62% in the 123 
breastfed infants (p=1.0, Table 2). A greater proportion of infants in the breastfeeding arm had 124 
detectable CMV DNA by one year of age (62.32% versus 42.54% in breast versus formula fed 125 
arm, p=0.001). The overall proportion of infants who tested positive in the first year (by either 126 
CMV DNA detection or serology) was also greater in the breastfed (80.43%) compared to the 127 
formula fed (60.45%) infants (p<0.001). 128 
The median time to CMV infection was 4.26 months in the breastfeeding arm and 9.87 months in 129 
the formula arm (Figure 2, p<0.001) and the probability of CMV infection at one year was 0.89 130 
in the breastfeeding arm and 0.69 in the formula feeding arm (p<0.001, Table 2). In a Cox 131 
proportional hazards model, breastfeeding was associated with a 1.67 fold increased risk of 132 
CMV acquisition (hazard ratio (HR): 1.67, 95%CI: 1.24-2.23, p=0.001) and this was 133 
independent of time-varying HIV infection status (multivariable HR: 1.61, 95% CI: 1.20-2.16, 134 
p=0.002). 135 
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Considering only the HIV-exposed uninfected infants, breastfed infants were significantly more 136 
likely than formula-fed infants to acquire CMV during the first year of life (86.67% versus 137 
57.66%, p<0.001). In addition, as seen in the cohort overall, time to CMV infection was 138 
significantly shorter for HIV-exposed uninfected infants in the breastfeeding arm compared to 139 
the formula feeding arm (log rank p-value = 0.001) with a median time to CMV infection of 5.80 140 
months versus 10.62 months (p<0.001), and a probability of infection at one year of 0.89 versus 141 
0.66, respectively (p<0.001, Figure 2). 142 
Sixty seven infants who were tested for CMV became HIV infected during the study, 47 in the 143 
breastfeeding arm and 20 in the formula feeding arm. The proportion of these HIV infected 144 
infants that were CMV infected (by DNA or serology) was similar between randomization arms 145 
(Table 2). HIV infected infants in both the breastfeeding arm and the formula feeding arm 146 
acquired CMV infection rapidly after birth, with a median time to CMV infection of 3.74 months 147 
and 3.90 months, respectively (p=0.9). Both arms had similarly high rates of CMV infection at 148 
one year (0.88 in the breastfeeding arm versus 0.79 in the formula feeding arm (p=0.5, Figure 2).  149 
Due to the high rate of treatment crossover in the formula arm of the study, all analyses were 150 
also performed classifying infants into feeding categories “as-treated”. This resulted in a total of 151 
165 infants being classified as breastfed and 102 being classified as formula-fed. Results of these 152 
analyses were similar to the intent to treat analyses (data not shown). 153 
Modes of CMV transmission The Kaplan-Meier models demonstrate nearly equivalent rates of 154 
CMV acquisition in infants from the two randomization arms during the first six weeks of life, 155 
followed by a plateau with few new infections diagnosed between 6-14 weeks, and a clear 156 
divergence between the two feeding arms at 14 weeks (Figure 2). Among HIV-exposed 157 
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uninfected breastfed infants assessed during the first year of life, we estimated 33.3% of CMV 158 
infections occurred peripartum based on detection of CMV by six weeks of life. Another 37.7% 159 
was estimated to have occurred through breastfeeding based on differences between 160 
breastfeeding and formula feeding arms. We estimated that another 29.0% occurred through non-161 
breast milk postpartum modes such as saliva and urine based on new infections after six weeks in 162 
infants who never breastfed (Table 3). Among HIV-infected breastfed infants, we estimated 163 
36.7% of CMV infections occurred peripartum, 43.3% occurred through breastfeeding, and 164 
20.0% occurred through non-breast milk modes. 165 
Discussion  166 
In a unique trial where feeding modality was randomized in HIV-infected women, we estimated 167 
the relative contribution of breast milk to CMV transmission. We found breastfeeding was 168 
associated with substantially earlier acquisition of CMV, and a higher rate of infant CMV 169 
infection at one year. In utero and intrapartum transmission likely  accounted for a large 170 
proportion of the peripartum CMV infections observed. These data highlight the potential 171 
challenges in preventing CMV transmission to HIV exposed infants. 172 
Breastfeeding conferred a 61% increase in CMV infection risk, controlling for infant HIV status, 173 
and breastfed infants acquired CMV nearly six months earlier than formula-fed infants. Because 174 
of our interval sampling, we allowed an upper boundary of six weeks to define peripartum 175 
transmissions but were unable to discriminate in utero and intrapartum infections; the 176 
equivalence of our Kaplan-Meier transmission models until the six week time-point suggests 177 
there were few breast milk transmissions detected during this time frame, after which CMV 178 
infections are observed at a high rate in the breastfed arm. Kumar and colleagues similarly found 179 
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that most CMV transmissions in a cohort of non-breastfed infants occurred before 14 weeks [14]. 180 
The waning of maternal antibodies may explain the large increase in infections detected at 14 181 
weeks; this pattern could thus be explained by an increase in susceptibility or unmasking of 182 
suppressed virus. We are unable to evaluate this with our current cohort sample archive, but this 183 
question has significance for understanding the immune mechanism of protection. Among HIV-184 
infected infants, we did not observe a difference in CMV transmission by feeding modality, and 185 
maternal and/or infant mechanisms may explain this observation. Immunosuppressed mothers 186 
are more likely to transmit HIV, and to be shedding CMV from multiple mucosal sites [21, 26], 187 
resulting in proportionally more transmissions via other routes. Infant immunosuppression may 188 
leave HIV-infected infants highly susceptible to all modes of CMV acquisition. Additionally, 189 
some infants acquired HIV before CMV and vice versa, which could impact our ability to 190 
discern a difference between arms in this stratum.  191 
The large contribution of peripartum transmissions may reflect the high frequency of CMV 192 
reactivation in the cervical mucosa of HIV infected women during their third trimester [21], 193 
which is associated with intrapartum transmission [12]. There was a high rate of in utero CMV 194 
acquisition in HIV-exposed uninfected infants in this cohort, consistent with earlier studies in 195 
HIV-infected cohorts from Kenya and elsewhere (3-11%, [9, 27, 28]). We did not detect any in 196 
utero CMV transmissions in the HIV-infected infants, which does not suggest an absence of in 197 
utero transmission in this group, but is more likely due to the small number of infants sampled at 198 
delivery. We thus cannot rule out a large contribution of in utero CMV transmissions in those 199 
detected <6 weeks of age, particularly among HIV-infected infants who are at higher risk for in 200 
utero CMV infection [6, 9]. 201 
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The rate of CMV transmission was also high in the infants randomized to formula, reaching 70% 202 
at one year. These infections were nearly equally distributed between peripartum and late 203 
transmissions. Peripartum CMV transmission rates were similar between breastfed and formula-204 
fed infants; and overall transmission rates were similar in both our intent-to-treat and as-treated 205 
analyses, suggesting that the high rate of CMV in the formula arm is not due to misclassification 206 
of feeding modality, but is due to the acquisition of CMV via non-breast milk modes of 207 
transmission. Infections can originate from other contacts from both within and outside the 208 
household [29] and because we did not sequence CMV in this study, we are unable to 209 
definitively link transmissions between mothers and infants.  210 
Although the rate of CMV infection was high among breastfed infants, it was lower than we 211 
reported previously in other cohorts (95% in HIV-exposed uninfected, 88-100% in HIV-infected 212 
[9]). We used dried blood spots for CMV diagnosis in this study, which have lower sensitivity 213 
than plasma at low viral loads. Using serology to screen CMV DNA-negative infants enabled us 214 
to identify most false-negative infants, however we were unable to verify final infection status in 215 
18 formula fed and 19 breastfed infants because they lacked plasma specimens after six months 216 
of age. Although we underestimate the true burden of CMV infection in the cohort, the very high 217 
rate of transmission enabled us to detect a difference between study arms despite some 218 
misclassification of outcome.  219 
In summary, breastfeeding conferred earlier CMV transmission, and a higher risk of transmission 220 
between HIV infected women and their infants. The significance of early CMV acquisition for 221 
outcomes in HIV-exposed uninfected infants is not yet clear, although there is increasing 222 
evidence to suggest HIV-exposed infants would benefit from a CMV vaccine. The high rate of 223 
early transmissions underscores the challenges for vaccine deployment in this population. An 224 
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alternative approach to preventing or delaying CMV infection in HIV-exposed infants may be to 225 
reduce CMV replication in the maternal breast milk and/or genital tract. In HIV-infected women, 226 
maternal immunosuppression is associated with a higher risk of infant CMV infection [21], 227 
suggesting maternal ART could reduce CMV transmission, but to date, only a small number of 228 
studies have examined this with variable findings [28, 30-32], and significant impacts on breast 229 
milk or cervical reactivation have not yet been demonstrated. As WHO Option B+ rolls out in 230 
sub-Saharan Africa and more women become pregnant while already on ART, it will be 231 
important to determine whether longer-term maternal HIV treatment changes this dynamic or 232 
whether additional measures to directly reduce CMV shedding are warranted.  233 
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Figure Legends:  
Fig. 1. CONSORT Diagram. Flow chart describes enrollment, allocation, follow-up and analysis 
for the main RCT. aInfants with a specimen collected by 14 weeks of age were eligible for 
inclusion in the CMV sub-study. 
Fig. 2. Infant CMV acquisition and containment. Kaplan-Meier survival functions show the 
probability of infant CMV infection during the first year of life in breastfed (solid line) and 
formula-fed (dashed line) infants, with right censoring at death or study exit. 
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Table 1. Characteristics of study population 
 Proportion (n) or Median (IQR)  
 Breastfed arm Formula-fed 
arm 
P value* 
Maternal enrollment characteristics    
N 138 134  
Age 23 (20, 27) 23 (21, 27) 0.9 
Parity 1 (0, 2) 1 (0, 2) 0.4 
Number of people in household 3 (2, 4) 3 (2, 4) 0.3 
CD4 cells/mm3 389 (261, 530) 441 (282, 549) 0.2 
Log10 HIV-1 RNA copies/ml
a 4.68 (4.15, 5.27) 4.59 (3.89, 5.12) 0.3 
Infant characteristics    
N 138 134  
Mother crossed over treatmentb 4.35% (6) 26.12% (35) <0.001 
Duration of breastfeeding (months) 14 (7, 18) 0 (0, 0.4) <0.001 
Acquired HIV 34.06% (47) 14.93% (20) <0.001 
Study visits 11 (6, 17) 13 (8, 18) 0.3 
Visits assessed for CMV 4 (3, 5) 5 (3, 5) 0.2 
Deaths 20.329% (28) 14.93% (20) 0.3 
*Mann-Whitney U test for continuous variables, Chi-square test for categorical variables. 
Notes. aMeasurement closest to delivery, n=120 in breastfed and n=119 in formula-fed arm. 
bDefined as ever breastfed (in formula-fed arm) and never breastfed (in breastfed arm). 
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Table 2: CMV acquisition in the two study arms 
 Proportion (n) or mean +SE  
 Breastfed 
arm 
Formula 
arm 
P value 
All infants N=138 N=134  
CMV infected at birth 3.62% (5) 3.73% (5) 1.0a 
CMV DNA+ 62.32% (86) 42.54% (57) 0.001 
CMV DNA-/serology + 18.12% (25) 17.91% (24) 1.0 
CMV DNA+ or serology+ 80.43% (111) 60.45% (81) P<0.001 
Probability of infection at one year 0.89 (+0.03) 0.69 (+0.05) <0.001b 
Median months to CMV infection 4.26 (+0.97) 9.87 (+1.27) <0.001b 
    
HIV-exposed uninfected infantsc N=90 N=111  
CMV infected at birth 5.56% (5) 4.50% (5) 0.8a 
CMV DNA+ 63.33% (57) 38.74% (43) 0.001 
CMV DNA-/serology + 23.33% (21) 18.92% (21) 0.4 
CMV DNA+ or serology+ 86.67% (78) 57.66% (64) P<0.001 
Probability of infection at one year 0.89 (+0.04) 0.66 (+0.05) <0.001b 
Median months to CMV infection 5.80 (+1.04) 10.62 (+0.71) <0.001b 
    
HIV-infected infants N=47 N=20  
CMV infected at birth 0 0 NA 
CMV DNA+ 59.57% (28) 65.00% (13) 0.7 
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CMV DNA-/serology + 8.51% (4) 10.00% (2) 1.0a 
CMV DNA+ or serology+ 68.08 % (32) 75.00% (15) P=0.6 
Probability of infection at one year 0.88 (+0.06) 0.79 (+0.10) 0.5b 
Median months to CMV infection 3.74 (+0.14) 3.90 (+1.60) 0.9b 
Notes. All estimates are presented as intent-to-treat. aFisher’s Exact Test, bZ-test 
cChildren with last CMV test at or after last HIV negative test and who never tested 
HIV positive. 
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Table 3: Relative modes of CMV acquisition. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Breastfed  Formula fed 
HIV-exposed uninfected infants   
Peripartum 33.3% 33.3% 
Breast milk 37.7% NA 
Non-breast milk 29.0% 66.7% 
HIV-infected infantsa   
Peripartum 36.7% 45.5% 
Breast milk 43.3% NA 
Non-breast milk 20.0% 54.5% 
Notes. Analysis was conducted as-treated. aEver diagnosed with HIV 
infection. 
